Artiva (ARTV) COO Jennifer Bush Receives Award (RSUs & Option)

What Happened

• Jennifer Bush, Chief Operating Officer (also CLO & Compliance Officer) of Artiva Biotherapeutics (ARTV), was granted two equity awards on September 9, 2026: 45,000 restricted stock units (RSUs) and a 135,000-share derivative award (an option-like award). Both were reported at an acquisition price of $0.00 (awarded, not purchased), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-09-09. Form 4 filed: 2026-09-11 (filed within the typical two-business-day window).
• Awards reported: 45,000 RSUs (footnote F1) and 135,000 derivative award (footnote F2). Reported price for both: $0.00.
• Vesting: F1 = RSU award under the Issuer’s 2024 Equity Incentive Plan. F2 = begins vesting Sept 8, 2026 at 1/48th per month over four years (standard 4-year monthly vesting).
• Shares owned after the transactions: not disclosed in the provided filing.
• No sale or purchase on the open market; these are compensation grants (no 10b5‑1 plan, tax withholding, or late-filing indicators noted in the provided info).

Context

• RSUs and option-style derivative awards are common executive compensation. RSUs convert to shares when vested; the derivative award will vest monthly over four years per F2 before shares become deliverable/exercisable. Because these are grants (not market purchases), they reflect compensation, not an immediate buying or selling signal.